Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9

Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9

Abstract The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tøri Vigeland Lerum, Niklas Nyboe Maltzahn, Pål Aukrust, Marius Trøseid, Katerina Nezvalova Henriksen, Trine Kåsine, Anne-Ma Dyrhol-Riise, Birgitte Stiksrud, Mette Haugli, Bjørn Blomberg, Bård Reiakvam Kittang, Asgeir Johannessen, Raisa Hannula, Saad Aballi, Anders Benjamin Kildal, Ragnhild Eiken, Tuva Børresdatter Dahl, Fridtjof Lund-Johansen, Fredrik Müller, Jezabel Rivero Rodriguez, Carin Meltzer, Gunnar Einvik, Thor Ueland, Inge Christoffer Olsen, NOR-SOLIDARITY Consortium, Andreas Barratt-Due, Trond Mogens Aaløkken, Ole Henning Skjønsberg
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/88393d531e5a4b23b4265b267e8189ee
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DLCO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO2/FiO2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DLCO, and persistent CT-findings was observed. Low pO2/FiO2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome.

Ejemplares similares